163 related articles for article (PubMed ID: 37771131)
21. Effects of bergapten on the pharmacokinetics of macitentan in rats both
Xu J; Zhou Q; Hou P; Wang Y; Geng P; Lu Z; Zhou Y; Dai D; Wang S
Front Pharmacol; 2023; 14():1204649. PubMed ID: 37492094
[TBL] [Abstract][Full Text] [Related]
22. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
Niwa T; Imagawa Y; Yamazaki H
Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
[TBL] [Abstract][Full Text] [Related]
24.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
25. Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.
Shen J; Wang B; Wang S; Chen F; Meng D; Jiang H; Zhou Y; Geng P; Zhou Q; Liu B
Drug Des Devel Ther; 2020; 14():2199-2206. PubMed ID: 32581516
[TBL] [Abstract][Full Text] [Related]
26. Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug-Drug Interactions of Selinexor with Posaconazole in Rats.
Zhou CJ; Wang HJ; Zhou CY; Li CF; Zhu MJ; Qiu XJ
Drug Des Devel Ther; 2021; 15():1561-1568. PubMed ID: 33883879
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants.
Yamaguchi Y; Akiyoshi T; Kawamura G; Imaoka A; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2021 Jun; 38():100384. PubMed ID: 33826998
[TBL] [Abstract][Full Text] [Related]
28. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
29. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
Lou Y; Song F; Cheng M; Hu Y; Chai Y; Hu Q; Wang Q; Zhou H; Bao M; Gu J; Zhang Y
PeerJ; 2023; 11():e15844. PubMed ID: 37581117
[TBL] [Abstract][Full Text] [Related]
30. Azoles, allylamines and drug metabolism.
Back DJ; Tjia JF; Abel SM
Br J Dermatol; 1992 Feb; 126 Suppl 39():14-8. PubMed ID: 1311943
[TBL] [Abstract][Full Text] [Related]
31. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models.
Yang L; Yan C; Zhang F; Jiang B; Gao S; Liang Y; Huang L; Chen W
Exp Anim; 2018 Feb; 67(1):71-82. PubMed ID: 29129847
[TBL] [Abstract][Full Text] [Related]
32. UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies.
Cui Y; Li Y; Fan L; An J; Wang X; Fu R; Dong Z
J Pharm Biomed Anal; 2021 Nov; 206():114360. PubMed ID: 34508926
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats.
Shi Y; Lu Z; Song W; Wang Y; Zhou Q; Geng P; Zhou Y; Wang S; Han A
Drug Des Devel Ther; 2024; 18():931-939. PubMed ID: 38560524
[TBL] [Abstract][Full Text] [Related]
34. In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
Deng G; Liu W; Ma C; Rong X; Zhang Y; Wang Y; Wu C; Cao N; Ding W; Guan H; Cheng X; Wang C
J Ethnopharmacol; 2019 May; 236():288-301. PubMed ID: 30872168
[TBL] [Abstract][Full Text] [Related]
35. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.
Mahmoud DE; Faraag AHI; Abu El-Wafa WM
World J Microbiol Biotechnol; 2021 Oct; 37(11):191. PubMed ID: 34632522
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Xie S; Ye L; Ye X; Lin G; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113353. PubMed ID: 32417565
[TBL] [Abstract][Full Text] [Related]
37. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
38. Interaction between flucloxacillin and azoles: Is isavuconazole next?
Van Daele R; Wauters J; Vandenbriele C; Lagrou K; Vos R; Debaveye Y; Spriet I
Mycoses; 2021 Dec; 64(12):1508-1511. PubMed ID: 34553797
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats.
Cui Y; Li Y; Guo C; Li Y; Ma Y; Dong Z
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080187
[TBL] [Abstract][Full Text] [Related]
40. UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats.
Li SL; Zhang Y; Cheng QS; Xin JZ; Dong ZQ; Qiu XJ
Infect Drug Resist; 2020; 13():3153-3161. PubMed ID: 32982330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
